Media Articles Related to Vantas (Histrelin Implant)
Surveilling Middle-Risk Prostate Cancer: Cautionary Data
Source: Medscape Hematology-Oncology Headlines [2017.01.10]
Active surveillance for the management of intermediate-risk prostate cancer is used at some cancer centers, but new data indicate that its use comes with increased risks for adverse outcomes
Medscape Medical News
Genetic basis of aggression in prostate cancer
Source: Genetics News From Medical News Today [2017.01.10]
New insights into the genetic drivers of prostate cancer that may inform treatment decisions are highlighted in two papers published online in Nature and Nature Communications this week.
Research helps explain why androgen-deprivation therapy doesn't work for many prostate cancers
Source: Genetics News From Medical News Today [2017.01.09]
Metastatic prostate cancer, or prostate cancer that has spread to other organs, is incurable.
Scientists uncover new way to defeat therapy-resistant prostate cancer
Source: Prostate / Prostate Cancer News From Medical News Today [2017.01.06]
A new study led by scientists from the Florida campus of The Scripps Research Institute (TSRI) sheds light on a signaling circuit in cells that drives therapy resistance in prostate cancer.
Light therapy 'a huge leap forward' for early prostate cancer treatment
Source: Clinical Trials / Drug Trials News From Medical News Today [2016.12.20]
In a new study, a novel light therapy called VTP led to complete remission in almost half of men with early localized prostate cancer.
Published Studies Related to Vantas (Histrelin Implant)
Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer. [2011.08.18]
Study Type - Therapy (individual cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Androgen deprivation therapy with a gonadotropin-releasing hormone agonist is an effective option for the palliative treatment of advanced prostate cancer. This study demonstrated the safety and efficacy of the histrelin acetate implant over successive one year treatment cycles for up to four years in an open-label extension trial. OBJECTIVE: * To evaluate the efficacy and tolerability of a once-yearly histrelin implant during an open-label extension of a pivotal study... CONCLUSIONS: * The once-yearly histrelin implant maintained testosterone suppression for repeated treatment cycles and was generally well tolerated. * The histrelin implant provides a clinically attractive option for long-term androgen deprivation therapy in patients with advanced prostate cancer seeking fewer office visits and repeated injections. (c) 2011 THE AUTHORS. BJU INTERNATIONAL (c) 2011 BJU INTERNATIONAL.
Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancer. [2010.08]
CONCLUSION: The GnRH agonist histrelin successfully suppressed testosterone over the entire study period. This effect was measured across a number of different clinical definitions of PSA response and clinical risk. The GnRH agonist therefore offers an effective therapy option in hormone treatment of prostate cancer.
Free alpha-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant. [2010.06]
BACKGROUND: Gonadotropin free alpha-subunit (FAS) levels paradoxically increase during GnRH agonist (GnRHa) treatment of central precocious puberty (CPP). The histrelin implant suppresses gonadotropins and estradiol (E(2)) levels for 1 yr, but effects on FAS have not been described. OBJECTIVES: We aimed to determine whether FAS levels remain elevated during treatment with the implant, to assess the dynamics of FAS after removal, and to ascertain the reliability of FAS for monitoring gonadotropin secretion... CONCLUSIONS: Compared to LH, FSH, and E(2), FAS responds more rapidly to implant removal and represents the most sensitive indicator of gonadotropin recovery after histrelin implant treatment.
Histrelin: in advanced prostate cancer. [2010.03.26]
Histrelin is a gonadotropin-releasing hormone agonist available in a diffusion-controlled reservoir drug delivery system for subcutaneous implantation. The subcutaneous histrelin implant provided sustained suppression of serum testosterone, luteinizing hormone (LH) and prostate-specific antigen levels for up to 1 year in patients with advanced prostate cancer in two phase II or III trials...
Drug-induced liver injury caused by the histrelin (Vantus) subcutaneous implant. [2010.01]
Drug-induced liver injury (DILI) is the leading cause of acute hepatic failure in the United States... The case of a patient with liver injury following a subcutaneous histrelin (Vantus) implant as therapy for advanced prostate cancer is presented.
Clinical Trials Related to Vantas (Histrelin Implant)
Histrelin Subcutaneous Implant in Children With Central Precocious Puberty [Completed]
The purpose of this study is to follow and collect additional medical and developmental
information on children after histrelin subcutaneous implant therapy is discontinued.
Prospective Multicentre Non-interventional Study of VANTASï¿½ for the Treatment of Patients With Advanced Prostate Cancer [Completed]
The aim of this non-interventional (observational) study is to document, in collaboration
with established urologists in Scandinavia, experience gained from routine use of Vantas®
for the treatment of patients with advanced prostate cancer. In this observational study
particular attention will be directed to treatment duration, quality of life and patient and
physician acceptance of the medicinal product for long-term therapy. Patient-based
measurement parameters such as quality of life and degree of satisfaction will allow
registration of information that extends beyond the clinical parameters. The knowledge
gathered will enable patient acceptance of long-term therapy to be evaluated. Clinical
outcome will also be documented by measuring serum testosterone and prostate specific
antigen (PSA) levels.
Vantas Implant Retrieval Study [Completed]
The main study objective was to collect implant retrieval information in 10 patients using
Vantas®, the 50 mg histrelin implant. Patients who had been identified as having a
difficult to locate or non-palpable implant were to have been enrolled. Sites were to adhere
to the instructions in the Package Insert, which included specialized investigations such as
ultrasound, CT, and MRI, to be used for the location and removal of implants.
Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer [Completed]
Objective was to evaluate the efficacy and safety of the histrelin acetate subdermal implant
(originally versus Lupron Depot-3 Month) in male patients with advanced prostate cancer
during 52 weeks of treatment with the implant. After consultation w/ FDA, design was
modified to eliminate the Lupron arm and continued the study as an open-label non-randomized
Primary endpoint was testosterone suppression, as assessed by the percent of patients whose
testosterone indicated chemical castration levels (<=50 ng/dL) through 52 weeks of treatment
with an implant.
Study of Histrelin Subdermal Implant in Patients With Prostate Cancer [Completed]
This trial was an open-label, multi-national, randomized, parallel treatment, active-control
multicenter study in adult males with documented metastatic prostate cancer disease who were
judged to be candidates for hormone therapy.